CardioQ-ODM+ wins Paris Hospital System Tender

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATIONS (EU) NO. 596/2014 ("MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

20 February 2018

Deltex Medical Group plc

("Deltex Medical", "Deltex" or "the Company")

CardioQ-ODM+ wins Paris Hospital System tender

Deltex Medical Group plc (AIM: DEMG), the global leader in Oesophageal Doppler Monitoring ("ODM"), is pleased to announce that its French distributor has been awarded a new tender to supply hospitals in Paris with CardioQ-ODM+ equipment.

The Company's French distribution partner, Gamida SA ("Gamida"), has won an eight year tender to supply CardioQ-ODM+ products to the Assistance Hopitaux Publique de Paris ('AHPP'). AHPP is the public hospital system of the city of Paris and its suburbs. It includes over 40 hospitals and is linked to the University of Paris. The tender is for a total of not less than 34,000 disposable probes and has a minimum value of over €4m over the eight year tender.

The terms of the tender, which replaces a previous tender originally awarded in 2011 and extended in 2014, requires Gamida to supply 70 new CardioQ-ODM+ monitors free of charge to AHPP hospitals. Deltex is supporting this requirement by supplying the monitors at very low margin and has this month received orders of £0.1m for 50 monitor systems, with the remaining 20 monitors to be supplied out of Gamida's own inventory.

Ewan Phillips, Deltex Medical's Chief Executive, commented:

"This is the largest value tender ever awarded anywhere for the Company's products and consolidates our strong market position in France, especially in Paris. France is our largest export market by volume and second only to the USA by value."

For further information, please contact:-

Notes for Editors

Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's proprietary ODM is the only technology to measure blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only company in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, ODM which is proven to reduce complications suffered by patients after surgery and save hospitals the costs of treating those complications.

Deltex Medical's CardioQ-ODM+ platform also now provides clinicians with two further advanced haemodynamic monitoring technologies. High Definition Impedance Cardiography is an entirely non-invasive monitoring technology which creates an electrical field across the chest and measures the disruption to this field when the heart pumps blood. Pulse Pressure Waveform Analysis uses peripheral blood pressure signal analysis to give doctors information on changes in the circulation and is particularly suited to monitoring lower risk or haemodynamically stable patients.

Company goal

Haemodynamic management is now becoming widely accepted as an important major new medical modality. Consequently, the Company's focus is on maximising value from the opportunities presented as enhanced haemodynamic management is adopted into routine clinical practice around the world. The Company aims to provide clinicians with a single platform, a 'haemodynamic workstation', which offers them a range of technologies from simple to sophisticated to be deployed according to the patient's condition and skill and expertise of the user. Doing this will enable the Company to partner healthcare providers to support modern haemodynamic management across the whole hospital.

The Company is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK, USA, Spain and Canada and through distribution arrangements in a further 30 countries.